Longitudinal analysis of peripheral immune cells in patients with multiple sclerosis treated with anti‐CD20 therapy

Documenti analoghi

• Repeated iv anti‐CD20 treatment in multiple sclerosis: Long‐term effects on peripheral immune cell subsets
  di: Julia Feige, et al.
  Pubblicazione: (2024)
• Phenotypic Changes in a Monocyte Cluster with High Interleukin‐1 Beta Expression during Long‐Term Anti‐ CD20 Therapy
  di: Mie Waede, et al.
  Pubblicazione: (2025)
• Inflammatory disease in people with multiple sclerosis treated with immune checkpoint inhibitors
  di: Saira Afzal, et al.
  Pubblicazione: (2024)
• In vivo evidence for cell body loss in cortical lesions in people with multiple sclerosis
  di: Eva A. Krijnen, et al.
  Pubblicazione: (2024)
• A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis
  di: Pietro Iaffaldano, et al.
  Pubblicazione: (2024)